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Abstract Fatigue is a common and disabling symptom in
patients with multiple sclerosis (MS), but its pathogenesis is
still poorly understood and consequently evidence-based
treatment options are limited. Bol et al. (J Behav Med
33(5):355–363, 2010) suggested a new model, which explains
fatigue in MS from a biopsychosocial perspective, including
cognitive-behavioral factors. For purposes of generalization to
clinical practice, cross-validation of this model in another
sample of 218 patients with MS was performed using structural
equation modeling. Path analysis indicated a close and ade-
quate global fit (RMSEA = 0.053 and CFI = 0.992). The
cross-validated model indicates a significant role for disease
severity, depression and a fear-avoidance cycle in explaining
MS-related fatigue. Modifiable factors, such as depression and
catastrophizing thoughts, propose targets for treatment options.
Our findings are in line with recent evidence for the effec-
tiveness of a new generation of cognitive behavioral therapy,
including acceptance and mindfulness-based interventions,
and provide a theoretical framework for treating fatigue in MS.
Keywords Multiple sclerosis  Fatigue  Catastrophizing 
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Introduction
Multiple sclerosis (MS) is characterized by a chronic
inflammation of the central nervous system, which results
in demyelination and atrophy, but has an unknown patho-
genesis and an unpredictable course. It is one of the most
common neurological disorder in young adults (Compston
& Coles, 2008) with a prevalence of 0.9 per 1000 (Hirtz
et al., 2007). Patients with MS report a variety of physical
and neuropsychiatric symptoms, with fatigue being the
most frequent and disabling symptom reported: 80–92 %
of patients with MS report fatigue, and 40–69 % rate
fatigue as their most disabling symptom (Bran˜as et al.,
2000; Giovannoni, 2006; Minden et al., 2006). Fatigue is a
major reason for decreased societal participation and is also
related to disability and poor quality of life.
Unfortunately, the multifactorial pathogenesis of fatigue
in MS is not completely understood, and evidence-based
treatment options remain scarce (Asano et al., 2014; Bol
et al., 2009; Kos et al., 2008; Pucci et al., 2007). Bol et al.
(2010) examined its multifactorial pathogenesis by fitting a
biomedical and a cognitive behavioral model in a sample
of 262 patients with MS using structural equation mod-
elling (SEM). Results showed that both models poorly
explained fatigue in MS, and based on previous research
and the results of their SEM analyses, they formulated a
new model. This final model was an integration of the first
two models, including both biomedical and cognitive-be-
havioral factors, and can be considered as the fatigue
equivalent of the fear-avoidance model of chronic muscu-
loskeletal pain (Crombez et al., 2012; Vlaeyen et al., 1995).
In this integrated model, catastrophizing about fatigue has
a central role: being fueled by depression, it mediated the
relationship between fatigue and fatigue related fear and
avoidance behavior (Bol et al., 2010).
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Catastrophizing about fatigue is defined as a fearful
interpretation of the meaning of fatigue by exaggerated
negative thinking, magnification of symptoms, and help-
lessness (e.g. ‘fatigue is terrible and I think it can never
improve’ or ‘when I feel tired, there is nothing I can do to
decrease its intensity’) (Lukkahatai & Saligan, 2013). If
fatigue is erroneously interpreted as a sign of pathology
over which one has little or no control, this could gradually
extend to a fear and avoidance of physical activities and
subsequently decreased physical abilities. According to the
fear-avoidance model, this would then lead to an increase
in fatigue concluding its cyclic pattern. Lukkahatai and
Saligan (2013) showed in their systematic review a con-
sistent strong positive correlation between catastrophizing
and fatigue severity in several clinical conditions that share
fatigue as one of their core symptoms, such as multiple
sclerosis, chronic fatigue syndrome, fibromyalgia and
cancer.
Besides the role of catastrophizing and fear-avoidance
behavior, previous research has shown a significant asso-
ciation between depression and fatigue in patients with MS,
independent of physical disability (Bakshi et al., 2000).
With regard to the direction of influence, a longitudinal
study of Patrick et al. (2009), including 2768 patients with
MS, showed that depression was one of the most important
predictors of fatigue at 1-year follow-up. With regard to
disease severity, Hadjimichael et al. (2008) showed a sig-
nificant positive correlation between disease severity and
fatigue in patients with MS, explaining that more physical
disability and neurological impairment are associated with
higher levels of fatigue.
This biopsychosocial model of Bol et al. (2010) inte-
grates these individual observations in a single model of
fatigue in MS, however cross-validation is necessary to
make a valid generalization and application to everyday
clinical practice possible. In the present study, we
hypothesize that the associations between fatigue, depres-
sion, catastrophizing and disease severity described by the
biopsychosocial model will explain fatigue in another large
group of MS patients. This cross-validation is important for
the understanding of the origin and perpetuating of fatigue
in patients with MS and will provide a theoretical frame-
work for treating fatigue in patients with MS.
Methods
Participants
Participants were recruited from hospital databases of the
department of Neurology of the Zuyderland Medical
Center in Sittard-Geleen, the Netherlands. A total of 621
Dutch-speaking patients with clinically definite MS
according to McDonald criteria (Polman et al., 2005), aged
between 18 and 65 years, were eligible for inclusion. Their
treating neurologist sent the initial letters to secure confi-
dentiality. A total of 403 patients were interested in par-
ticipating and responded (65 % response rate). These
patients were sent an information letter, an informed con-
sent and questionnaires. A total of 312 participants returned
the forms (77 % response rate). Questionnaires were filled
in between May 2011 and September 2011. Participants
who previously participated in the study of Bol et al.
(2010) (N = 86) were excluded. Informed consent was
obtained from all participants included in the study.
Patients did not receive any financial compensation for
their participation.
Measures
Basic demographic information
Age, gender, level of education, employment status, mar-
ital status and use of psychopharmacological drugs were
obtained by a demographic inventory filled in by the
patients. The level of education was based on the highest
completed level of education and divided into three cate-
gories: primary school (low level of education); junior
vocational training (middle level of education); senior
vocational training or academic training (high level of
education). Medical data, such as disease duration, disease
course, MS subtype and disease severity were collected
from the hospital databases.
Disease severity
Disease severity was assessed with the Expanded Disability
Status Scale (EDSS) (Kurtzke, 1983). This scale comprises
the evaluation of 8 functioning systems (pyramidal, cere-
bellar, brainstem, mental, bowel and bladder, visual-optic,
sensory and other). The EDSS score, based on the evalu-
ation of an experienced neurologist, ranges from 0 to 10,
where 0 indicates a normal neurological examination and
10 indicates death due to MS. Recent EDSS scores
(\3 months) were extracted from the hospital database.
Physical disability
Physical disability was assessed with the physical dimen-
sion of the SF-36, a Dutch translation of the Short Form
Health Survey developed and validated by Aaronson et al.
(1998). Bol et al. (2010) showed a high reliability of this
measure in patients with MS. It consists out of four sub-
scales; physical functioning, role limitations due to physi-
cal health problems, bodily pain, and general health. Each
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standardized subscore of the physical dimension ranges
from 0 to 100, where a total score of 400 resembles optimal
physical health and no physical disability.
Fear avoidance
Fear avoidance was assessed with the fatigue version of the
Tampa Scale for Kinesiophobia (TSK-F) (Silver et al.,
2002), which is an adjusted version of the TSK for chronic
pain (Miller et al., 1991; Vlaeyen et al., 1995). Silver et al.
(2002) replaced in all 17 items the word ‘pain’ by the word
‘fatigue’ to make the questionnaire suitable for investiga-
tion of fatigue-related fear and avoidance behavior. The
score ranges from 17 to 68, where a higher score indicates
a higher level of fear-avoidance behavior. This instrument
is found to be valid (Silver et al., 2002) and reliable in
patients with MS (Bol et al., 2010; Silver et al., 2002).
Catastrophizing
Catastrophizing about fatigue was assessed with the Fati-
gue Catastrophizing Scale (FCS), which is an adapted
version of the Pain Catastrophizing Scale (PCS) (Sullivan
et al., 1995). Psychometric properties of the PCS are ade-
quate (Osman et al., 2000). The PCS consists out of 13
items measuring the self-reported frequency of catastro-
phizing thoughts about experienced pain. As with the TSK
adaptation, Bol et al. (2010) adapted all the PCS items by
replacing the word ‘pain’ by the word ‘fatigue’. Scoring
alternatives ranged from ‘strongly disagree’ to ‘strongly
agree’. As in the study of Bol et al. (2010), three MS-
related items were added (‘When I am tired, this is a signal
there is something wrong in my brain’, ‘When I am tired,
this is a warning for physical decline’, ‘When I am tired,
this is a sign that my MS is getting worse’). In total 16
items were administered and the score ranges from 0 to 64
with higher scores indicating higher intensity of catastro-
phizing. Bol et al. (2010) showed a high reliability of this
measure in patients with MS. In the current sample the
reliability was excellent (a = 0.94).
Fatigue
Fatigue was assessed with the Abbreviated Fatigue Ques-
tionnaire (AFQ), a valid and reliable instrument (Alberts
et al., 1997). Administration to patients with MS also
revealed its reliability (Bol et al., 2010). This questionnaire
is a selection of four items of the Checklist Individual
Strength (CIS-20) developed by Vercoulen et al. (1999).
Items are rated on a 7-point Likert scale with scoring
alternatives ranging from ‘Yes, that is true’ to ‘No, that is
not true’. The final score ranges from 4 till 28, with higher
scores indicating a higher severity of physical fatigue.
Depression
Depression was assessed with the subscale depression of
the Hospital Anxiety and Depression Scale (HADS) (Zig-
mond & Snaith, 1983), a valid and reliable screening
instrument for patients with MS (Honarmand & Feinstein,
2009). The total score ranges from 0 to 21 with a higher
score indicating a higher intensity of depression. Honar-
mand and Feinstein (2009) showed that patients with MS
with a score of 8 or higher are likely depressed.
Statistical analyses
Data analyses were performed using SPSS 22.0.0.0 for
Windows (SPSS Inc., Chicago, IL). If less than 25 % of the
items of questionnaires, or more than 50 % if a question-
naire consisted of four items, were missing, missing values
were imputed by the mean of the remaining non-missing
items of the scale (27 values across 24 participants).
Descriptive statistics were used to describe the sample. No
variable was significantly skewed (skewness \-1 or [1)
nor were there any significant outliers (all cases were
within 1.5 interquartile ranges from the upper or lower
quartile). Cronbach’s alpha was used to test reliability of
all questionnaires. Relations between all variables were
analyzed by Pearson-correlations. An alpha level of .05
was used for all statistical tests.
Cross-validation was analyzed with structural equation
modeling in Mplus 7 (Muthe´n & Muthe´n, 1998–2012). The
biopsychosocial model of Bol et al. (2010) was specified in a
path analysis using manifest variables only (no measurement
model). Error terms were assumed to be uncorrelated and left
free. The Root Mean Square Error of Approximation
(RMSEA) was used as a global fit index, because parsimony
and sample size are taken into account. RMSEA represents
the lack of fit in comparison with a perfect fit and should
therefore be low. RMSEA values up to 0.05 indicate a close
fit, values between 0.05 and 0.08 indicate an acceptable fit,
values between 0.08 and 0.10 indicate a mediocre fit, and
those greater than 0.10 indicate a poor fit. Furthermore, the
comparative fit index (CFI) was used, because it represents
the relative improvement of the model in comparison with a
baseline model, usually a model in which all observed
variables are uncorrelated. Values larger than 0.95 indicate a
good fit and values between 0.90 and 0.95 indicate an
acceptable fit. Furthermore, the Chi square test of model fit,
Standardized Root Mean Square Residual (SRMR) and
Tucker–Lewis Index (TLI) were also reviewed as fit indexes.
A non-significant Chi square test of model fit indicates a
J Behav Med (2016) 39:815–822 817
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good fit. SRMR values smaller than .08 indicate an accept-
able fit, whereas values smaller than 0.05 indicate a good fit.
TLI values higher than .90 are acceptable and values higher
than .95 represent a good fit. To control for possible nor-
mality assumption violation, a robust maximum likelihood
estimator for standard errors, also known as the ‘Huber
Sandwich Estimator’, was used (Huber, 1967). Modification
indices were inspected to consider further fine-tuning of the
model to the data-at-hand in an exploratory fashion. Finally,
direct and total effects of the significant variables were cal-
culated.
Results
Patient sample
A total of two participants were excluded due to too many
missing values ([25 % of items of questionnaires missing).
Finally, six participants were excluded due to a missing
value in the single exogenous variable, EDSS, which was
necessary for proper structural equation modeling (SEM)
analysis. This resulted in a final sample of 218 outpatients
(53 men, 165 women) with an average age of 48.0 years
(SD = 10.5, range 19–65). Most of them had a relapsing
remitting disease course (n = 153), while 43 patients had a
secondary progressive disease course and 21 patients had a
primary progressive disease course (1 missing value). The
mean disease duration was 8.8 years (SD = 7.5, range
0–30 years) with an average EDSS score of 3.6 (SD = 1.9,
range 0.5–8.0), which resembles a moderate disease
severity. Around 24 % of the sample showed high levels of
catastrophizing, using the cutoff score of 30 as suggested
by Sullivan et al. (1995) for patients with pain. Around
34 % of the sample showed high levels of fear avoidance,
using the cutoff score of 37 as suggested by Vlaeyen et al.
(1995) for patients with pain. See Table 1 for a summary of
all patient characteristics.
Reliability and correlations
Table 2 resembles means, standard deviations, ranges,
reliability indexes (Cronbach’s alphas) for all measures and
their intercorrelations (Pearson). All questionnaires had a
satisfactory internal consistency (range 0.69–0.94). All
intercorrelations were statistically significant (p\ 0.01)
with the strongest correlation between depression and
physical disability. Higher levels of depression were
associated with lower levels of physical ability (r = -0.58,
p\ 0.001). The weakest correlation was found between
disease severity and catastrophizing about fatigue
(r = 0.21, p\ 0.01).
Structural equation modeling analyses
Figure 1 shows the results of the path analysis of the new
model proposed by Bol et al. (2010). The RMSEA value
was 0.053 (90 % CI 0.000–0.112), which indicates an
acceptable fit. The SRMR, CFI and TLI value were
respectively 0.023, 0.992 and 0.979, indicating a good fit.
The Chi square test of model fit was non-significant
(p = 0.138) also indicating a good fit. Furthermore, all
hypothesized relationships were statistically significant.
The total explained variance of fatigue measured with the
AFQ was 44 %. All variables provided a significant con-
tribution to this explained variance. Both depression
(b = .27) and physical disability (b = -.45) were directly
associated with fatigue. There were no modification
indexes given, suggesting that no alternative specification
of relationships between the variables were identified
which could improve the model. We added a relationship
from disease severity to depression, due to its significance
in the second model postulated by Bol et al. (2010), but this
worsened the global fit of our model and was subsequently
removed. Moreover, we ran an additional post hoc analysis
to study the variance in fatigue explained by the fear
avoidance cycle. For this, we omitted the paths to and from
depression and disease severity (see Fig. 1) from the
model. This showed that physical disability, fear-avoid-
ance, catastrophizing and their underlying associations
explain 39 % of the variance in fatigue, compared with
Table 1 Patient characteristics (n = 218)
Variable Value
Gender % female (n) 76 (165)
Age in years [mean (SD)] 48.0 (10.5) range 19.6–65.6
Disease duration in years [mean
(SD)]
8.8 (7.5) range 0.1–30.2
Disease course
Relapsing remitting (%) 71
Secondary progressive (%) 20
Primary progressive (%) 9
Use of disease modifying drugs
(% yes, % no)
61/39
Use of psychopharmaca (% yes,
% no)
25/75
Level of education (% low, %
middle, % high)
24/37/39
Marital status (% partner, % no
partner)
82/28
Employment status (% working,
% not working)
32/68
818 J Behav Med (2016) 39:815–822
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44 % of the total model. See Table 3 for an overview of the
standardized direct, indirect and total effects on fatigue.
Discussion
Due to the high prevalence of fatigue in patients with MS
and its disabling impact on everyday activities and quality
of life, understanding its pathogenesis and identifying its
modifiable contributing factors are crucial. Bol et al. (2010)
showed that neither a biomedical nor a cognitive-behav-
ioral model explained fatigue in 262 patients with MS, but
suggested a new biopsychosocial model integrating ele-
ments of the previously tested models, i.e. disease severity,
depression and fear-avoidance cycle. To generalize and
apply this model to everyday clinical practice, cross-vali-
dation of this integrated model in another sample was
needed. We hypothesized that the biopsychosocial model
of Bol et al. (2010) can explain fatigue in MS in another
large sample.
Table 2 Means, standard deviations (SD), ranges, Cronbach’s alphas (a) and Pearson-correlations of all measures
Mean (SD) Range a 2 3 4 5 6
1. Disease severity (EDSS) 3.6 (1.9) 0.5–8 – .23** .21* .22** .29** -.48**
2. Fatigue (AFQ) 19.7 (6.8) 4–28 0.90 – .55** .34** .54** -.63**
3. Catastrophizing about fatigue (FCS) 19.9 (14.1) 0–56 0.94 – – .58** .57** -.55**
4. Fatigue-related fear and avoidance (TSK-F) 34.3 (8.3) 20–68 0.73 – – – .41** -.42**
5. Depression (HADS-D) 6.0 (4.0) 0–17 0.82 – – – – -.58**
6. Physical disability (SF-physical) 208.5 (92.1) 25–400 0.69 – – – – –
EDSS Expanded Disability Status Scale, AFQ Abbreviated Fatigue Questionnaire, FCS Fatigue Catastrophizing Scale, TSK-F Fatigue Version of
the Tampa Scale for Kinesiophobia, HADS-D depression subscale of the Hospital Anxiety and Depression Scale, SF-physical Physical scale of
the Short Form Health Survey
* p\ 0.01; ** p\ 0.001
Fig. 1 Path analysis of the
biopsychosocial model of fatigue
in multiple sclerosis (n = 218).
Note Values shown are
standardized regression
coefficients and based on cross-
sectional data. Light blue
variables and its relationships
represent the fear-avoidance cycle
within the model. Explained
variances are provided in
parentheses. Please note that the
scale of physical disability is
inverted. *p\ 0.05; **p\ 0.01;
***p\ 0.001 (Color
figure online)
J Behav Med (2016) 39:815–822 819
123
The SEM analyses presented in this study, explaining
fatigue in a new sample of 218 patients with MS, showed
good support of the biopsychosocial model of Bol et al.
(2010). Catastrophizing, depression, physical disability,
disease severity and fear avoidance all contribute signifi-
cantly to fatigue, either directly or indirectly. Comparing
the results to that of the original publication, the global fit
indices RMSEA and CFI even slightly improved respec-
tively from 0.085 towards 0.053 and from 0.983 towards
0.992. This implies an increase in fit from mediocre to
acceptable (RMSEA) or even good (CFI).
The biopsychosocial model indicates a significant role
for disease severity, depression and an adapted fear
avoidance model in explaining MS-related fatigue. This
integrated model partly overlaps with a recently formulated
model by Wu et al. (2015) explaining post-stroke fatigue.
They suggest also an integration of biological and psy-
chological variables, including depressive symptoms,
coping and behavioral factors. Also in stroke patients, an
intervention including CBT elements showed a long term
reduction in fatigue (Zedlitz et al., 2012). Moreover,
Zedlitz et al. (2012) stated that the addition of graded
activity to the cognitive elements, which focuses on
improvement of physical disability, resulted in a longer
endurance of the fatigue reducing effects.
Translating the biopsychosocial model of Bol et al.
(2010) to clinical practice in MS, the model indicates
several modifiable factors, such as the fatigue-enhancing
cycle of fear avoidance and depression, which form
important targets for interventions. Diagnosing and treating
depression could be a first step to treat MS related fatigue.
Depression is with a life-time prevalence of approximately
50 % very prevalent in MS and probably underdiagnosed
and untreated (Feinstein, 2011; Maier et al., 2015). When
depression is treated, for instance with cognitive behavioral
therapy (CBT) (Hind et al., 2014), it is likely that fatigue is
also reduced. Next, CBT focusing on changing catastro-
phizing thoughts about fatigue could help fatigued MS
patients (Knoop et al., 2011; Moss-Morris et al., 2012; van
Kessel et al., 2008). Knoop et al. (2011) concluded that
changes in thoughts about fatigue play a crucial role in
CBT for fatigue in MS. Hoogerwerf et al. (submitted)
showed that also the third generation CBT, Mindfulness
Based Cognitive Therapy (MBCT) is an effective inter-
vention for severely fatigued MS patients. Patients were
not only less fatigued after MBCT, but also less depressed
and less catastrophizing about fatigue. This suggests that
catastrophizing can be reduced not only by altering the
content of thoughts such as in regular CBT, but even by
disengaging from the maladaptive thoughts about fatigue.
There are several limitations to this study, which should
be taken into account when interpreting the results and
could be addressed in future studies. First of all, the design
is cross-sectional making it impossible to draw firm con-
clusions about causality and temporal relations in the dis-
ease process. More prospective and longitudinal studies are
needed to confirm the proposed causal relationships. Sec-
ondly, postal questionnaires were used which made us
unable to compare responders with non-responders. The
response rate was favorable (77 %), but lower in compar-
ison with Bol et al. (2010) (93 % response rate). A possible
explanation could be related to the fact that more ques-
tionnaires were included which demanded more time and
energy of the participants. As a result, we cannot exclude
the possibility of a selection bias. Thirdly, all data were
self-reported and are therefore sensitive to retrospective
bias and response styles. Fourthly, our main outcome
measure, the AFQ, is a questionnaire consisting out of four
items. Despite its sufficient validity and reliability, Hore-
mans et al. (2004) argued that the AFQ lacks precision at
the individual patient level. Future studies should include
fatigue questionnaires which are validated in MS patients,
such as the Fatigue Severity Scale or the Modified Fatigue
Impact Scale (Rietberg et al., 2010). Finally, other factors,
some even modifiable, such as sleep disorders, cognitive
impairments and maladaptive coping styles, were not
assessed and therefore lacking in the biopsychosocial
model. Their inclusion could increase the explained vari-
ance of the model due to their previously established
influences on fatigue in MS (Rabinowitz & Arnett, 2009;
Strober & Arnett, 2005; Ukueberuwa & Arnett, 2014).
Furthermore, the overall anxiety level and other distorted
Table 3 Standardized direct, indirect and total effects on fatigue
Variable Direct Indirect Total
Fear-avoidance (TSK-F) 0.000 0.103** 0.103**
Physical disability (SF-physical) -0.447*** -0.173*** -0.620***
Depression (HADS-D) 0.274*** 0.024* 0.298***
Disease severity (EDSS) 0.000 0.288*** 0.288***
Catastrophizing (FCS) 0.000 0.054* 0.054*
TSK-F Fatigue Version of the Tampa Scale for Kinesiophobia, SF-physical Physical scale of the Short Form Health Survey, HADS-D depression
subscale of the Hospital Anxiety and Depression Scale, EDSS Expanded Disability Status Scale, FCS Fatigue Catastrophizing Scale
* p\ 0.05; ** p\ 0.01; *** p\ 0.001
820 J Behav Med (2016) 39:815–822
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cognitive thinking habits besides catastrophizing, in which
elements of rumination, magnification and helplessness are
embedded (Sullivan et al., 1995), could possibly be another
useful addition for future studies due its modifiable char-
acter and insight in effective therapeutic elements.
Despite these limitations, this cross-validation of the
biopsychosocial model of Bol et al. (2010) forms an
important next step in explaining MS-related fatigue and
highlights a promising role for CBT. The integrated model
supports the clinical practice guidelines that both biological
and psychological factors should be taken into account
during the clinical assessment and treatment of fatigue in
MS (CBO, 2013; Van Kessel & Moss-Morris, 2006). It is
expected that development and evaluation of targeted
psychological interventions will help improving the
biopsychosocial model of MS related fatigue.
Acknowledgments We would like to thank all the patients who took
part in this study; the therapists, psychological assistants and MS
nurses of Zuyderland Medical Center; Dr. Myreen Moors for her
effort in gathering and monitoring the data acquisition; Prof. Dr.
Raymond Hupperts for his kind cooperation and time investment.
Compliance with ethical standards
Conflict of interest Melloney L. M. Wijenberg, Sven Z. Stapert,
Sebastian Ko¨hler and Yvonne Bol declare that they do not have any
conflict of interest.
Human and animal rights and Informed consent All procedures
were approved by and in accordance with the ethical standard of the
medical ethics committee of Zuyderland Medical Center and with the
1964 Helsinki declaration and its later amendments. Informed consent
was obtained from all patients for being included in the study.
References
Aaronson, N. K., Muller, M., Cohen, P. D., Essink-Bot, M.-L.,
Fekkes, M., Sanderman, R., et al. (1998). Translation, validation,
and norming of the Dutch language version of the SF-36 Health
Survey in community and chronic disease populations. Journal
of Clinical Epidemiology, 51, 1055–1068.
Alberts, M., Smets, E., Vercoulen, J., Garssen, B., & Bleijenberg, G.
(1997). ‘Verkorte vermoeidheidsvragenlijst’: een practisch hulp-
middel bij het scoren van vermoeidheid. Nederlands Tijdschrift
voor Geneeskunde, 141, 1526–1530.
Asano, M., Berg, E., Johnson, K., Turpin, M., & Finlayson, M. L.
(2014). A scoping review of rehabilitation interventions that
reduce fatigue among adults with multiple sclerosis. Disability
and Rehabilitation, 37(9), 729–738.
Bakshi, R., Shaikh, Z., Miletich, R., Czarnecki, D., Dmochowski, J.,
Henschel, K., et al. (2000). Fatigue in multiple sclerosis and its
relationship to depression and neurologic disability. Multiple
Sclerosis, 6, 181–185.
Bol, Y., Duits, A. A., Hupperts, R. M., Vlaeyen, J. W., & Verhey, F. R.
(2009). The psychology of fatigue in patients with multiple
sclerosis: A review. Journal of Psychosomatic Research, 66, 3–11.
Bol, Y., Duits, A. A., Lousberg, R., Hupperts, R. M., Lacroix, M. H.,
Verhey, F. R., et al. (2010). Fatigue and physical disability in
patients with multiple sclerosis: A structural equation modeling
approach. Journal of Behavioral Medicine, 33, 355–363.
Bran˜as, P., Jordan, R., Fry-Smith, A., Burls, A., & Hyde, C. (2000).
Treatments for fatigue in multiple sclerosis: A rapid and
systematic review. Health Technology Assessment (Winchester,
England), 4, 1.
CBO. (2013). Richtlijn multipele sclerose 2012. Houten: Bohn Stafleu
Van Loghum.
Compston, A., & Coles, A. (2008). Multiple sclerosis. The Lancet,
372, 1502–1517. doi:10.1016/S0140-6736(08)61620-7
Crombez, G., Eccleston, C., Van Damme, S., Vlaeyen, J. W., &
Karoly, P. (2012). Fear-avoidance model of chronic pain: The
next generation. The Clinical Journal of Pain, 28, 475–483.
Feinstein, A. (2011). Multiple sclerosis and depression. Multiple
Sclerosis Journal, 17, 1276–1281.
Giovannoni, G. (2006). Multiple sclerosis related fatigue. Journal of
Neurology, Neurosurgery and Psychiatry, 77, 2–3.
Hadjimichael, O., Vollmer, T., & Oleen-Burkey, M. (2008). Fatigue
characteristics in multiple sclerosis: The North American
Research Committee on Multiple Sclerosis (NARCOMS) sur-
vey. Health and Quality of Life Outcomes, 6, 100. doi:10.1186/
1477-7525-6-100
Hind, D., Cotter, J., Thake, A., Bradburn, M., Cooper, C., Isaac, C.,
et al. (2014). Cognitive behavioural therapy for the treatment of
depression in people with multiple sclerosis: A systematic
review and meta-analysis. BMC Psychiatry, 14, 5.
Hirtz, D., Thurman, D., Gwinn-Hardy, K., Mohamed, M., Chaudhuri,
A., & Zalutsky, R. (2007). How common are the ‘‘common’’
neurologic disorders? Neurology, 68, 326–337.
Honarmand, K., & Feinstein, A. (2009). Validation of the Hospital
Anxiety and Depression Scale for use with multiple sclerosis
patients. Multiple Sclerosis, 15(12), 1518–1524. doi:10.1177/
1352458509347150.
Hoogerwerf, A. E., Bol, Y., Lobbestael, J., Hupperts, R. M., & van
Heugten, C. M. Mindfulness based cognitive therapy is feasible
and effective in severely fatigued patients with Multiple
Sclerosis: A waiting list controlled study (submitted).
Horemans, H. L., Nollet, F., Beelen, A., & Lankhorst, G. J. (2004). A
comparison of 4 questionnaires to measure fatigue in postpo-
liomyelitis syndrome. Archives of Physical Medicine and
Rehabilitation, 85, 392–398.
Huber, P. J. (1967). The behavior of maximum likelihood estimates
under nonstandard conditions. Paper presented at the proceed-
ings of the fifth Berkeley symposium on mathematical statistics
and probability.
Knoop, H., Van Kessel, K., & Moss-Morris, R. (2011). Which
cognitions and behaviours mediate the positive effect of
cognitive behavioural therapy on fatigue in patients with
multiple sclerosis? Psychological Medicine, 42, 205–213.
Kos, D., Kerckhofs, E., Nagels, G., & D’Hooghe, M. (2008). Origin
of fatigue in multiple sclerosis: Review of the literature.
Neurorehabilitation and Neural Repair, 22, 91–100.
Kurtzke, J. F. (1983). Rating neurologic impairment in multiple
sclerosis an expanded disability status scale (EDSS). Neurology,
33, 1444.
Lukkahatai, N., & Saligan, L. N. (2013). Association of catastro-
phizing and fatigue: A systematic review. Journal of Psychoso-
matic Research, 74, 100–109.
Maier, S., Balasa, R., Buruian, M., Maier, A., & Bajko, Z. (2015).
Depression in multiple sclerosis—Review. Romanian Jounal of
Neurology, 14, 22.
Miller, R. P., Kori, S. H., & Todd, D. D. (1991). The tampa scale.
Unpublished report. Tampa, FL.
Minden, S. L., Frankel, D., Hadden, L., Perloff, J., Srinath, K. P., &
Hoaglin, D. C. (2006). The Sonya Slifka longitudinal multiple
J Behav Med (2016) 39:815–822 821
123
sclerosis study: Methods and sample characteristics. Multiple
Sclerosis, 12, 24–38. doi:10.1191/135248506ms1262oa
Moss-Morris, R., Dennison, L., Landau, S., Yardley, L., Silber, E., &
Chalder, T. (2012). A randomized controlled trial of cognitive
behavioral therapy (CBT) for adjusting to multiple sclerosis (the
saMS trial): Does CBT work and for whom does it work?
Journal of Consulting and Clinical Psychology, 81, 251–262.
doi:10.1037/a0029132
Muthe´n, L. K., & Muthe´n, B. O. (1998–2012). Mplus user’s guide
(7th ed.). Los Angeles, CA: Muthe´n & Muthe´n.
Osman, A., Barrios, F. X., Gutierrez, P. M., Kopper, B. A., Merrifield,
T., & Grittmann, L. (2000). The Pain Catastrophizing Scale:
Further psychometric evaluation with adult samples. Journal of
Behavioral Medicine, 23, 351–365.
Patrick, E., Christodoulou, C., & Krupp, L. (2009). Longitudinal
correlates of fatigue in multiple sclerosis. Multiple Sclerosis, 15,
258–261.
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P.,
Kappos, L., et al. (2005). Diagnostic criteria for multiple
sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Annals
of Neurology, 58, 840–846.
Pucci, E., Branas, P., D’Amico, R., Giuliani, G., Solari, A., & Taus,
C. (2007). Amantadine for fatigue in multiple sclerosis.
Cochrane Database of Systematic Reviews. doi:10.1002/
14651858.CD002818.pub2.
Rabinowitz, A. R., & Arnett, P. A. (2009). A longitudinal analysis of
cognitive dysfunction, coping, and depression in multiple
sclerosis. Neuropsychology, 23, 581.
Rietberg, M., Van Wegen, E., & Kwakkel, G. (2010). Measuring
fatigue in patients with multiple sclerosis: Reproducibility,
responsiveness and concurrent validity of three Dutch self-report
questionnaires. Disability and Rehabilitation, 32, 1870–1876.
Silver, A., Haeney, M., Vijayadurai, P., Wilks, D., Pattrick, M., &
Main, C. (2002). The role of fear of physical movement and
activity in chronic fatigue syndrome. Journal of Psychosomatic
Research, 52, 485–493.
Strober, L. B., & Arnett, P. A. (2005). An examination of four models
predicting fatigue in multiple sclerosis. Archives of Clinical
Neuropsychology, 20, 631–646.
Sullivan, M. J., Bishop, S. R., & Pivik, J. (1995). The pain
catastrophizing scale: Development and validation. Psycholog-
ical Assessment, 7, 524.
Ukueberuwa, D. M., & Arnett, P. A. (2014). Evaluating the role of
coping style as a moderator of fatigue and risk for future
cognitive impairment in multiple sclerosis. Journal of the
International Neuropsychological Society, 20, 751–755.
Van Kessel, K., & Moss-Morris, R. (2006). Understanding multiple
sclerosis fatigue: A synthesis of biological and psychological
factors. Journal of Psychosomatic Research, 61, 583–585.
van Kessel, K., Moss-Morris, R., Willoughby, E., Chalder, T.,
Johnson, M. H., & Robinson, E. (2008). A randomized
controlled trial of cognitive behavior therapy for multiple
sclerosis fatigue. Psychosomatic Medicine, 70, 205–213.
Vercoulen, J., Alberts, M., & Bleijenberg, G. (1999). De checklist
individuele spankracht (CIS). Gedragstherapie, 32, 131–136.
Vlaeyen, J. W., Kole-Snijders, A. M., Rotteveel, A. M., Ruesink, R.,
& Heuts, P. H. (1995). The role of fear of movement/(re) injury
in pain disability. Journal of Occupational Rehabilitation, 5,
235–252.
Wu, S., Mead, G., Macleod, M., & Chalder, T. (2015). Model of
understanding fatigue after stroke. Stroke, 46, 893–898.
Zedlitz, A. M., Rietveld, T. C., Geurts, A. C., & Fasotti, L. (2012).
Cognitive and graded activity training can alleviate persistent
fatigue after stroke a randomized, controlled trial. Stroke, 43,
1046–1051.
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and
depression scale. Acta Psychiatrica Scandnavica, 67, 361–370.
822 J Behav Med (2016) 39:815–822
123
